Latest Cost Savings News

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

Virgin Australia Holdings (ASX:VGN) posted a 13.4% rise in underlying EBIT to $753 million for FY26, declaring a fully franked dividend of 7.6 cents per share, its first since relisting. The airline’s transformation program, fleet renewal, and operational resilience underpin its improved financial and customer metrics.

Beonic Limited grew revenue by 5.2% to $23.3 million in FY26, halving its loss and achieving positive operating cash flow, underpinned by a landmark Moroccan airport contract and product innovation.

Global Health Limited trimmed its FY26 net loss by 12.5% to A$758,220, driven by a 5.5% lift in recurring SaaS revenue and a 20% cut in employee costs aided by AI integration, though going concern risks remain.

Alliance Aviation Services posted a statutory loss of $90.9 million in FY2026, driven by a $164.8 million impairment on its Fokker fleet, while underlying profit remained within guidance. The company is realigning around core FIFO operations, fleet renewal, and cost discipline, supported by a $40 million equity raise and revised Qantas wet lease terms.

IVE Group posted a mixed FY26 with a 1.8% revenue decline but underlying profit growth, strategic acquisitions, and notable progress in AI commercialization and climate disclosures.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Future Generation Global's half-year profit fell sharply as its portfolio lagged global benchmarks, yet it boosted its fully franked interim dividend reflecting confidence in its income sustainability.

WiseTech Global posted a record $1.4 billion in revenue for FY26, driven by the e2open acquisition and AI-led efficiencies, while underlying net profit rose 29%. The company outlines a confident FY27 growth outlook amid ongoing integration and innovation.